EXACT Therapeutics AS – Primary Insider Notice

OSLO/LONDON, 9 June 2022: Reference is made to the stock exchange release by EXACT Therapeutics AS (“EXACT-Tx”, “the Company” Euronext Growth: EXTX) on 9 June 2022 regarding a share capital increase in connection with the Company's restricted stock unit (RSU) programme.

Anders Wold, Chair of EXACT-Tx, has subscribed for 2,414 shares at NOK 19.00 per share. Following this transaction, Anders Wold will hold 2,414 shares in EXACT-Tx.

ENDS

For more information, please contact: 

Per Walday, CEO
EXACT Therapeutics
Email: per.walday@exact-tx.com

Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.